Synexa Insights
The Latest Insights From Our Scientists
Where Does Bioanalysis Fit into Drug Discovery Pipelines?
Bioanalysis is foundational for investigational therapeutic agents. This blog post will define the bioanalysis of molecules and highlight its beneficial role in drug discovery pipelines.…
EBF OS 2025: My Key Highlights
A unifying message across EBF 2025 was that bioanalytical science is transitioning from technical execution to decision support. For years,…
S-Pindolol: The Fight Against Cancer Cachexia
Cancer cachexia is a silent thief. It robs patients of strength, stripping away muscle and fat, leaving them frail and…
The Silence of the Genes: Unlocking Antisense Oligonucleotide Therapies for the Renin-Angiotensin-Aldosterone System
The field of gene therapy is rapidly evolving, with antisense oligonucleotide therapies emerging as powerful tools for modulating gene expression.…
From Signals to Systems: Olink Proteomics as a Cornerstone of Synexa’s Biomarker Strategy
We have entered a new era of modern science, where therapeutic innovation is reshaping the field of medicine.…
GMP Grade Ligand Binding and Potency Assays – Frequently Asked Questions
Good Manufacturing Practice ligand binding and potency assays are essential for ensuring the quality, safety, and regulatory compliance of biopharmaceutical…
Validating Immunity: How ELISpot Data Shaped the AELIX-003 HIV Cure Trial
We are proud to share our laboratory’s role in a landmark clinical study published in Nature Communications, titled “Safety, immunogenicity…
From Pathways to Proof: Targeted Phosphoproteomics and PTM Analysis with LC-MS/MS
Quadrupole mass spectrometry (LC-MS/MS) has long established itself as the workhorse of bioanalysis for small molecules, valued for its high…
Establishing Biosimilarity: Regulatory and Scientific Expectations
A biosimilar is defined as a biologic product, highly similar to a reference or originator, with no clinically meaningful differences…
Why The Future Of Precision Medicine Will Be Defined By The Quality And Strategy Of Biomarker Signatures
We’re in the midst of a paradigm shift in biomarker science. No longer academic luxuries or exploratory afterthoughts, biomarker signatures…
Radiopharmaceutical Drug Development: A Bioanalytical Lab Perspective
The radiopharmaceutical industry has traditionally experienced steady but modest growth, primarily driven by its established role in diagnostics and nuclear…
Building a bioanalytical workflow for a vaccine study: The key assays and considerations
The COVID-19 pandemic put vaccines under the spotlight again, and from a scientific perspective at least, innovations have abounded.…
Quantitative Analysis of Oligonucleotides: An out of the box LC-MS/MS approach
Oligonucleotide therapeutics have revolutionised the field of medicine over the last decade due to their potential for treating a broad…
Improving the quality of human health
Contact us
Discuss biomarker and bioanalytical solutions to accelerate your therapeutic pipeline
